Skip to main content

Table 4 Polymorphisms and toxicity due to treatment of colorectal cancer patients

From: Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival

Polymorphism Toxicity, n (%) p
ERCC1-rs11615 Stomatitisa  
 T/T 14/70 (20.0)  
 C/T + C/C 8/94 (8.5) 0.03
ERCC1-rs11615 Nausea  
 T/T 24/37 (64.9)  
 C/T + C/C 48/58 (82.8) 0.04
ERCC2-rs13181 Eye reactions  
 A/A 7/37 (18.9)  
 A/C + C/C 27/58 (46.6) 0.006
ERCC2-rs13181 Thrombocytopenia  
 A/A 8/36 (22.2)  
 A/C + C/C 31/59 (52.5) 0.004
ERCC2-rs238406 Thrombocytopenia  
 C/C 16/28 (57.1)  
 C/A + A/A 23/67 (34.3) 0.03
ERCC2-rs13181 Dose reduction/discontinuationa  
 A/A 38/70 (54.3)  
 A/C + C/C 69/96 (71.9) 0.02
  1. NOTE-aPatients who received adjuvant chemotherapy